Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 20/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14892388 | 0.93 | ENPP2 (0.82) | ENPP2 | |
| SCHEMBL47766 | 0.92 | ENPP2 (0.80) | ENPP2 | |
| SCHEMBL14892821 | 0.91 | ENPP2 (0.81) | ENPP2 | |
| SCHEMBL18799221 | 0.90 | ENPP2 (0.80) | ENPP2 | |
| SCHEMBL14891286 | 0.89 | ENPP2 (0.65) | ENPP2 | |
| SCHEMBL14891432 | 0.89 | ENPP2 (0.77) | ENPP2 | |
| SCHEMBL12697637 | 0.89 | ENPP2 (0.73) | ENPP2 | |
| SCHEMBL14891576 | 0.88 | ENPP2 (0.74) | ENPP2 | |
| SCHEMBL14891826 | 0.88 | ENPP2 (1.00) | ENPP2 | |
| SCHEMBL14891145 | 0.88 | ENPP2 (1.00) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3002285-B1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-9974777-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9974777-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9974777-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9862721-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-09 | — | — | US | disclosed |
| US-9862721-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-09 | — | — | US | disclosed |
| US-20170189386-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20170189386-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20170189386-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-9636330-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-02 | — | — | US | disclosed |
| US-9006246-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006246-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| EP-2687531-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2014-01-22 | — | — | EP | disclosed |
| EP-2687531-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20130345426-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-26 | — | — | US | disclosed |
| EP-2592081-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109699-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-20130109699-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-20130109699-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| WO-2012005227-A1 | TETRAHYDROCARBOLINE DERIVATIVE | 小野薬品工業株式会社 (JP) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345426-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | ENPP2 1/4885 |
| US-20170189386-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | ENPP2 1/4885 |
| US-20130109699-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | ENPP2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.